Perspectives on Target Selection: How Companies Approach a Critical Decision

9:00 AM - 10:00 AM (EDT), Thursday, June 8, 2023 ・ Session Room 203
While often evaluated by the modality they employ or therapeutic area in which they focus, a company’s approach to selecting the biological targets it pursues can mean the difference between success and failure. Operating in a highly competitive environment, and with a deeper understanding of biology than ever before, the ability to articulate a clear and compelling strategy to target selection is critical at all stages of growth. This strategy can be driven by a variety of factors, including advances in research, patient need, a target's "druggability," and the characteristics of a preferred modality. Representing companies with different therapeutic approaches, and at various stages of corporate and scientific development, the panel of experienced biopharma leaders will discuss how their approach to target selection broadly impacts their business, from financing to resource allocation, to partnerships and collaborations with academic institutions and other companies, and internal and external communications.
Senior Business Editor
Genetic Engineering & Biotechnology
Senior Vice President, Head of Research
Kymera Therapeutics
CSO, President of Research
Q32 Bio Inc.
Founder, President and CEO
Seismic Therapeutic
VP, Solid Tumor Oncology
Bristol Myers Squibb